<DOC>
	<DOCNO>NCT00000793</DOCNO>
	<brief_summary>To assess efficacy , safety , tolerability amitriptyline hydrochloride versus mexiletine hydrochloride reduce pain intensity patient HIV-related painful peripheral neuropathy . No large-scale control clinical trial symptomatic therapy painful HIV-related neuropathy attempt . Both amitriptyline mexiletine useful management painful neuropathy ; however , associate certain toxicity . In comparative study amitriptyline mexiletine , benztropine mesylate also include active placebo mimic side effect study drug .</brief_summary>
	<brief_title>A Phase II/III Double-Blind Study Amitriptyline Mexiletine Painful Neuropathy HIV Infection</brief_title>
	<detailed_description>No large-scale control clinical trial symptomatic therapy painful HIV-related neuropathy attempt . Both amitriptyline mexiletine useful management painful neuropathy ; however , associate certain toxicity . In comparative study amitriptyline mexiletine , benztropine mesylate also include active placebo mimic side effect study drug . Patients randomize receive amitriptyline , mexiletine , benztropine mesylate active placebo mimic mild side effect associate amitriptyline mexiletine . Doses gradually increased 4 week minimum effective dose MTD reach , patient treat least 4 additional week final dose gradually taper . Neurologic exams perform screen end treatment . Intensity pain rat twice daily patient . Patients follow Weeks 2 , 4 , 8 , 10 day completely taper drug . PER 3/16/95 AMENDMENT : Patients pain relief 14 day initiation study therapy may dose double increased maximum allowable dose , whichever low . Then improvement occur within 14 day dose increase , patient option discontinue study medication .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<mesh_term>Mexiletine</mesh_term>
	<mesh_term>Benztropine</mesh_term>
	<mesh_term>Amitriptyline , perphenazine drug combination</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Aspirin acetaminophen . Nonsteroidal antiinflammatory agent . Opiates . Pyridoxine ( accompany isoniazid ) . ddI , ddC , d4T , 3TC stable dose . AZT . Cimetidine stable dose . NOTE : Per 3/16/95 amendment , Lactaid may take lactoseintolerant patient effect lactose placebo capsule . Concurrent Treatment : Allowed : Acupuncture . Patients must : Documented HIV infection . Painful peripheral neuropathy . NOTE : Patients ACTG blind study dideoxynucleosides ddI , ddC , d4T encourage enroll study . Prior Medication : Allowed : Prior ddI , ddC , d4T , 3TC , stable dose least 8 week prior study entry . Prior cimetidine stable dose least 2 week prior study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Diabetes mellitus . Neurological disease sufficient severity confound evaluation peripheral neuropathy , myelopathy without neuropathy . ( NOTE : Patients myelopathy AND painful peripheral neuropathy eligible . ) Electrocardiogram ( EKG ) indicate malignant arrhythmia cardiac conduction disturbance ( second third degree AV block , anterior hemiblock , prolong QT interval ) . Suicidal thought sufficient severity require treatment antidepressant medication . Concurrent Medication : Excluded : Phenytoin carbamazepine ( unless stable dose 8 week prior study entry ) . Capsaicin . Any MAO inhibitor antidepressant , tricyclic tetracyclic antidepressant , certain serotonin reuptake inhibitor ( fluoxetine , paroxetine , venlafaxine ) , mexiletine ( except dispense study ) . Disopyramide . Procainamide . Quinidine . Tocainide . Flecainide acetate . Encainide . Lidocaine . Cisplatin . Vincristine . Chloramphenicol , disulfiram , ethionamide glutethimide , gold , hydralazine , iodoquinol , metronidazole , nitrofurantoin , ribavirin ( patient onset clear worsen painful peripheral neuropathy attribute previously take drug ) . Any investigational drug 3TC ( except permission protocol team ) . Terfenadine ( concurrent ketoconazole ) . Patients follow prior condition exclude : Documented history cardiac disease . History allergy , intolerance , tricyclic antidepressant , mexiletine , benztropine . Prior Medication : Excluded : Prior disopyramide . Prior procainamide . Prior quinidine . Prior tocainide . Prior flecainide acetate . Prior encainide . Prior lidocaine . Cisplatin vincristine within 8 week prior study entry . Chloramphenicol , disulfiram , ethionamide glutethimide , gold , hydralazine , iodoquinol , metronidazole , nitrofurantoin , ribavirin within 8 week prior study entry ( patient onset clear worsen painful peripheral neuropathy attribute take drug ) . Any MAO inhibitor antidepressant , tricyclic tetracyclic antidepressant , certain serotonin reuptake inhibitor ( fluoxetine , paroxetine , venlafaxine ) , mexiletine , within 4 week prior study entry . More 50 percent change weekly dosage pain control medication within 2 week prior study entry . Per 3/16/95 amendment : ddI , ddC , d4T , 3TC within 8 week prior study entry ONLY IF dideoxynucleoside dose suspend permanently discontinue . Risk Behavior : Excluded : Active drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Peripheral Nervous System Diseases</keyword>
	<keyword>Amitriptyline</keyword>
	<keyword>Pain</keyword>
	<keyword>Mexiletine</keyword>
	<keyword>benzatropine methanesulfonate</keyword>
	<keyword>Parasympatholytics</keyword>
</DOC>